Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.

Authors :: Wei AH
Roboz GJ
Dombret H
Dohner H
Schuh AC
Montesinos P
Selleslag D
Bondarenko SN
Prebet T
Lai Y
Skikne B
Beach CL
Ravandi F
Source :: Haematologica [Haematologica] 2023 Oct 01; Vol. 108 (10), pp. 2820-2825. Date of Electronic Publication: 2023 Oct 01.
Publication Year :: 2023

Subjects :: Humans
Antimetabolites, Antineoplastic therapeutic use
Remission Induction
Azacitidine therapeutic use
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute mortality

Full Text Access

Tools